Business Wire

NY-IFF

4.6.2019 16:02:08 CEST | Business Wire | Press release

Share
IFF Launches a New Purpose and Brand Identity Designed to Challenge the Industry

Regulatory News:

IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, has been breaking boundaries since its beginning in 1889. Today, IFF is kicking off a new era that celebrates its history of innovation, customer-centric focus, new capabilities and the drive to deliver for customers of any size. IFF’s new purpose: To redefine & transform how we live in and care for the resources of our world, shows its commitment to being more than a flavors and fragrances company – it advances its promise to do better for people and planet – and in doing so, supporting its customers in their efforts to do the same. A new brand identity and mantra of Uncommon Sense encourages customers and employees alike to reject convention in favor of delivering what the world needs.

Andreas Fibig, IFF Chairman and CEO, says that the new brand is designed to challenge expectations: “Five years ago, we promised to redefine IFF’s role in the flavors and fragrances industry. Since that time, we have nearly doubled our product offerings, sales and world-class talent and expanded our customers base by more than tenfold. We have become a leader in sustainability -- responsible for many industry firsts – and galvanized our employees to embrace their role in making the world a better place.”

Mr. Fibig continued, “With such a diverse and expansive organization, we needed a purpose that can connect us globally. So, we’ve created something new in our industry – a purpose that both embraces and goes beyond our day-to-day and helps us reach higher for the good of people and our planet. That’s the essence of who we are. We want to be ahead, doing more and doing it better than the rest. Our new purpose and Uncommon Sense brand are aiming high, but I believe our purpose should bring our people together while making us stretch beyond what we think is possible today.”

Uncommon Sense, the Company’s new mantra, challenges its employees to rethink conventional wisdom to create a culture where ideas and possibilities flow. Mr. Fibig said, “This is the type of approach that has led to some of the biggest dreams and greatest inventions of our world. These are the ideas that have allowed us to fly, that have sent humans to the moon; that let us dream of living on Mars. Uncommon Sense opens the door for us to make the impossible, possible.”

The brand is underpinned by three pillars: Question Everything, Champion Creators, and Do More Good. Unapologetically bold and purposefully inclusive, the new identity expands the definition of IFF’s work and reaches further than ever before. To learn more about IFF’s next era, watch the new brand video at www.iff.com .

# # #

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.comTwitter  , Facebook , Instagram , and LinkedIn .

Contact:

IFF Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye